



Claresa Levetan, M.D., Fellow, American College of Endocrinology, is a noted endocrinologist with expertise spanning diverse areas of diabetes. She has been internationally recognized for the translation of science and technology into improved health care options for patients with diabetes. In 2004, Dr. Levetan co-founded CureDM, Inc., and served as its Chief Scientific and Medical Officer. Her co-founding of CureDM represents the culmination of her 25 years of experience as a practicing endocrinologist and diabetes researcher. Her work has resulted in the filing and issuance of various patents of a human peptide to be used as an innovative therapy with the potential of reversing diabetes.

In 2007, Dr. Levetan received the American College of Endocrinology's Highest Distinction in Clinical Endocrinology Award that is presented annually to the endocrinologist recognized as having achieved distinction in the field of clinical endocrinology; and has a sustained record of devotion to teaching the art and science of endocrinology. She served as an associate editor of the journals, *Clinical Diabetes* and *Diabetes Forecast*. Upon completion of two terms as associate editor of the American Diabetes Association's journal, *Clinical Diabetes*, Dr. Irl Hirsch, the Editor in Chief, wrote in an editorial, "Dr. Resa Levetan is perhaps the most creative physician I have ever met. Her ideas for developing interesting articles, translating new information to others, and getting physicians, patients, and their families involved with diabetes to obtain better outcomes are truly inspired."

Dr. Levetan has been on the forefront of diabetes research and has been published in many medical journals including the *American Journal of Medicine*. She received the Roche Diagnosed prestigious award for innovative diabetes research and has been an invited visiting scholar at Harvard University's Joslin Diabetes Center, as well as an invited Grand Rounds speaker at the Harvard Hospitals. She received has led research teams in the areas of methods to prevent and reverse diabetes, and was an investigator on the NIH's Diabetes Prevention Program and Women's Health Initiative. She was the co-chair of the American College of Endocrinology's Diabetes Outpatient and Inpatient Consensus Conferences, which established the first specific goals for patients both before and after meals. Dr. Levetan was an invited expert on the NIH's international consensus panel on inpatient management of diabetes and served on the steering committee of the NIH and CDC's National Diabetes Education Program (NDEP) and Medicare's National Committee for Quality Assurance's (NCQA's) and Diabetes Quality Improvement Project (DQIP). She served on the Board of Directors of the American Association of Clinical Endocrinologists and was on the Board of Trustees of the American College of Endocrinology.

Dr. Levetan is a graduate of Emory University School of Medicine. She was Professor and Chief of Endocrinology, Diabetes at Hahnemann Medical College and the Medical College of Pennsylvania, now Drexel University College of Medicine. She is in private practice at Chestnut Hill Hospital in Philadelphia.